Altimmune, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Jerome Durso (President and CEO) and Greg Weaver (CFO) certified on August 12, 2026 that Altimmune's Q2 2026 10-Q fairly presents financial condition and results of operations. Both officers affirmed disclosure controls and internal controls over financial reporting are effective and no material weaknesses or fraud affecting internal controls were identified. This is routine SEC certification language required under Sarbanes-Oxley.
Why this rating
Boilerplate SOX certification exhibit with no operational or financial disclosures. Absence of material weakness flags is normal; such filings are administrative routine.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.